Comparable stake leader
7. Cooperative Ua Lsp
SEC ownership of Evommune, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0002044725.
Disclosed value leader
7. Cooperative Ua Lsp
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- EVMN on NYSE
- Parsed ownership sources
- 3/4/5, 13D/G, and 13F
- Largest SEC-reported holder
- 7. Cooperative Ua Lsp
- Latest 13D/G holder
- 7. Cooperative Ua Lsp
- Latest parsed ownership date
- 31 Mar 2026
- Issuer CIK
- 0002044725
- Issuer location
- Palo Alto, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Evommune, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
7. Cooperative Ua Lsp
Disclosed value leader
7. Cooperative Ua Lsp
Comparable rows
50/50
Latest evidence
31 Mar 2026
3/4/5
13D/G
13F
Lead comparable stake: 15%
13D/G row: 7. Cooperative Ua Lsp
Showing 1-8 of 50 holder rows.
Quick read
7. Cooperative Ua Lsp leads the comparable SEC ownership view at 15%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens 7. Cooperative Ua Lsp's linked filing trail.
Comparable ownership
Top 5
7. Cooperative Ua Lsp
15%
Pivotal bioVenture Partners Fund ...
11%
RA CAPITAL MANAGEMENT, L.P.
9.7%
Andera Partners
6%
Isabel Verduyn van Weegen
15%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| 7. Cooperative Ua Lsp |
3/4/5
13D/G
Director, 10%+ Owner · LSP 7 Cooperatieve U.A.
|
15%
from 13D/G
|
$147,438,166
5,288,313 shares
|
— | 17 Feb 2026 |
| Pivotal bioVenture Partners Fund I, L.P. |
13D/G
3/4/5
Nan Fung Group Holdings Limited · Director, 10%+ Owner
|
11%
|
$69,158,608
3,435,599 shares
|
$0 | 31 Dec 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
3/4/5
Company · Director
|
9.7%
from 13D/G
|
$80,341,728
3,494,638 shares
|
— | 31 Mar 2026 |
| Andera Partners |
13F
13D/G
Company
|
6%
from 13D/G
|
$43,620,352
1,897,362 shares
|
— | 31 Mar 2026 |
| Isabel Verduyn van Weegen |
3/4/5
Director, 10%+ Owner
|
15%
|
$147,438,166
5,288,313 shares
|
— | 17 Feb 2026 |
| Robert Lorne Hopfner |
3/4/5
Director, 10%+ Owner
|
9.4%
|
$63,219,381
3,372,001 shares
|
+$17,350 | 19 Dec 2025 |
| EQT Fund Management S.a r.l. |
13F
Company
|
14%
|
$113,332,263
4,929,633 shares
|
— | 31 Mar 2026 |
| Pivotal bioVenture Partners Investment Advisor LLC |
13F
Company
|
5.4%
|
$44,300,420
1,926,943 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$1,606,771.
Buys
$17,350
Insiders: 1
Sells
$1,624,121
Insiders: 5
Net
-$1,606,771
Shares: -70,928
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 1,000
Shares: 71,928
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 71,928 | $0 | $1,624,121 | -$1,624,121 |
| 3-6 | 1,000 | 0 | $17,350 | $0 | +$17,350 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-15 of 15 reporting-owner rows connected to Evommune, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
15
Largest Forms 3/4/5 holder
7. Cooperative Ua Lsp
Net 12M change
-$1,606,770
Latest report
02 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| 7. Cooperative Ua Lsp | Director, 10%+ Owner | $147,438,166 | Mixed | 17 Feb 2026 | ||
| Isabel Verduyn van Weegen | Director, 10%+ Owner | $147,438,166 | Mixed | 17 Feb 2026 | ||
| RA CAPITAL MANAGEMENT, L.P. | Director | $75,562,968 | Mixed | 17 Feb 2026 | ||
| Robert Lorne Hopfner | Director, 10%+ Owner | $63,219,381 | +$17,350 | +0.03% | Mixed | 19 Dec 2025 |
| Luis C. Pena | President & CEO, Director | $14,505,755 | -$381,736 | -2.6% | Filing P/S | 01 Jun 2026 |
| Eugene Bauer | Chief Medical Officer, Director | $4,831,393 | Mixed | 16 Apr 2026 | ||
| Gregory S. Moss | Chief Business & Legal Officer | $1,461,856 | -$324,711 | -18% | Mixed | 28 May 2026 |
| Kyle Carver | Chief Financial Officer | $1,355,211 | -$415,117 | -23% | Filing P/S | 28 May 2026 |
| Janice Suzann Drew | Chief of Dev. Operations | $1,209,444 | Mixed | 16 Apr 2026 | ||
| Jeegar Pravinkumar Patel | Chief Scientific Officer | $1,055,204 | -$379,462 | -26% | Filing P/S | 01 Jun 2026 |
| David E. Cohen | Director | $376,480 | -$123,094 | -25% | Filing P/S | 02 Jun 2026 |
| Pivotal bioVenture Partners Fund I, L.P. | Director, 10%+ Owner | Mixed | 07 Nov 2025 | |||
| Derek DiRocco | Director | Mixed | 05 Nov 2025 | |||
| Arthur S. Kirsch | Director | Mixed | 02 Jun 2026 | |||
| Benjamin F. Mcgraw III | Director | Mixed | 02 Jun 2026 |
Recent insider transactions for Evommune, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Benjamin F. Mcgraw III | EVMN | Stock Option (Right to buy) | Award | 15,673 | 15,673 | 02 Jun 2026 | Direct | |||
| Arthur S. Kirsch | EVMN | Stock Option (Right to buy) | Award | 15,673 | 15,673 | 02 Jun 2026 | Direct | |||
| David E. Cohen | EVMN | Common Stock | Sale | -25.6% | $123,094 | $20.33 | -6,056 | 17,609 | 02 Jun 2026 | Direct |
| David E. Cohen | EVMN | Stock Option (Right to buy) | Award | 15,673 | 15,673 | 02 Jun 2026 | Direct | |||
| Jeegar Pravinkumar Patel | EVMN | Common Stock | Sale | -26.4% | $379,462 | $22.74 | -16,687 | 46,403 | 01 Jun 2026 | Direct |
| Jeegar Pravinkumar Patel | EVMN | Common Stock | Options Exercise | 27.2% | 13,512 | 63,090 | 01 Jun 2026 | Direct | ||
| Jeegar Pravinkumar Patel | EVMN | Employee Stock Option (Right to Buy) | Options Exercise | -31.5% | -13,512 | 29,330 | 01 Jun 2026 | Direct | ||
| Luis C. Pena | EVMN | Common Stock | Sale | -2.56% | $381,736 | $22.74 | -16,787 | 637,896 | 01 Jun 2026 | Direct |
| Gregory S. Moss | EVMN | Common Stock | Sale | -19% | $324,711 | $22.83 | -14,223 | 60,835 | 28 May 2026 | Direct |
| Gregory S. Moss | EVMN | Common Stock | Options Exercise | 23.4% | 14,223 | 75,058 | 28 May 2026 | Direct | ||
| Gregory S. Moss | EVMN | Employee Stock Option (Right to Buy) | Options Exercise | -22.9% | -14,223 | 47,845 | 28 May 2026 | Direct | ||
| Kyle Carver | EVMN | Common Stock | Sale | -23.4% | $415,117 | $22.84 | -18,175 | 59,335 | 28 May 2026 | Direct |
| Kyle Carver | EVMN | Common Stock | Options Exercise | 24% | 15,000 | 77,510 | 28 May 2026 | Direct | ||
| Kyle Carver | EVMN | Employee Stock Option (Right to Buy) | Options Exercise | -13.4% | -15,000 | 96,731 | 28 May 2026 | Direct | ||
| Jeegar Pravinkumar Patel | EVMN | Employee Stock Option (Right to Buy) | Award | 69,315 | 69,315 | 16 Apr 2026 | Direct | |||
| Janice Suzann Drew | EVMN | Employee Stock Option (Right to Buy) | Award | 73,892 | 73,892 | 16 Apr 2026 | Direct | |||
| Eugene Bauer | EVMN | Employee Stock Option (Right to Buy) | Award | 51,117 | 51,117 | 16 Apr 2026 | Direct | |||
| Kyle Carver | EVMN | Employee Stock Option (Right to Buy) | Award | 98,946 | 98,946 | 16 Apr 2026 | Direct | |||
| Gregory S. Moss | EVMN | Employee Stock Option (Right to Buy) | Award | 115,279 | 115,279 | 16 Apr 2026 | Direct | |||
| Luis C. Pena | EVMN | Employee Stock Option (Right to Buy) | Award | 291,420 | 291,420 | 16 Apr 2026 | Direct | |||
| 7. Cooperative Ua Lsp | EVMN | Common Stock | Award | 7.28% | 358,680 | 5,288,313 | 17 Feb 2026 | See footnote | ||
| Isabel Verduyn van Weegen | EVMN | Common Stock | Award | 7.28% | 358,680 | 5,288,313 | 17 Feb 2026 | By LSP 7 Cooperatief U.A. | ||
| Ra Capital Management, L.P. | EVMN | Common Stock | Award | 1.34% | 35,868 | 2,710,293 | 17 Feb 2026 | See Footnotes | ||
| Robert Lorne Hopfner | Common Stock | Purchase | 33% | $17,350 | $17.35 | 1,000 | 4,026 | 19 Dec 2025 | By Trust | |
| Luis C. Pena | Common Stock | Tax liability | -4.12% | -28,138 | 654,683 | 09 Dec 2025 | Direct | |||
| Jeegar Pravinkumar Patel | Common Stock | Tax liability | -13.2% | -7,513 | 49,578 | 09 Dec 2025 | Direct | |||
| Gregory S. Moss | Common Stock | Tax liability | -18.3% | -13,624 | 60,835 | 09 Dec 2025 | Direct | |||
| Janice Suzann Drew | Common Stock | Tax liability | -6.96% | -5,074 | 67,794 | 09 Dec 2025 | Direct | |||
| Kyle Carver | Common Stock | Tax liability | -17.5% | -13,290 | 62,510 | 09 Dec 2025 | Direct | |||
| Eugene Bauer | Common Stock | Tax liability | -0.54% | -1,478 | 270,818 | 09 Dec 2025 | Direct | |||
| Eugene Bauer | Employee Stock Option (Right to Buy) | Award | 100,000 | 100,000 | 08 Dec 2025 | Direct | ||||
| Isabel Verduyn van Weegen | Common Stock | Purchase | 46.4% | 1,562,500 | 4,929,633 | 07 Nov 2025 | By LSP 7 Cooperatief U.A. | |||
| Isabel Verduyn van Weegen | Common Stock | Conversion of derivative security | 3,367,133 | 3,367,133 | 07 Nov 2025 | By LSP 7 Cooperatief U.A. | ||||
| Isabel Verduyn van Weegen | Series C Preferred Stock | Conversion of derivative security | -100% | -6,585,011 | 0 | 07 Nov 2025 | By LSP 7 Cooperatief U.A. | |||
| Isabel Verduyn van Weegen | Series B Preferred Stock | Conversion of derivative security | -100% | -5,090,000 | 0 | 07 Nov 2025 | By LSP 7 Cooperatief U.A. | |||
| Isabel Verduyn van Weegen | Series A Preferred Stock | Conversion of derivative security | -100% | -15,493,466 | 0 | 07 Nov 2025 | By LSP 7 Cooperatief U.A. | |||
| Jeegar Pravinkumar Patel | Common Stock | Conversion of derivative security | 5.89% | 3,175 | 57,091 | 07 Nov 2025 | Direct | |||
| Jeegar Pravinkumar Patel | Series B Preferred Stock | Conversion of derivative security | -100% | -25,000 | 0 | 07 Nov 2025 | Direct | |||
| Janice Suzann Drew | Common Stock | Conversion of derivative security | 2.23% | 1,587 | 72,868 | 07 Nov 2025 | Direct | |||
| Janice Suzann Drew | Series B Preferred Stock | Conversion of derivative security | -100% | -12,500 | 0 | 07 Nov 2025 | Direct | |||
| 7. Cooperative Ua Lsp | Common Stock | Purchase | 46.4% | 1,562,500 | 4,929,633 | 07 Nov 2025 | Direct | |||
| 7. Cooperative Ua Lsp | Common Stock | Conversion of derivative security | 3,367,133 | 3,367,133 | 07 Nov 2025 | Direct | ||||
| 7. Cooperative Ua Lsp | Series C Preferred Stock | Conversion of derivative security | -100% | -6,585,011 | 0 | 07 Nov 2025 | Direct | |||
| 7. Cooperative Ua Lsp | Series B Preferred Stock | Conversion of derivative security | -100% | -5,090,000 | 0 | 07 Nov 2025 | Direct | |||
| 7. Cooperative Ua Lsp | Series A Preferred Stock | Conversion of derivative security | -100% | -15,493,466 | 0 | 07 Nov 2025 | Direct | |||
| Kyle Carver | Common Stock | Conversion of derivative security | 4.37% | 3,175 | 75,800 | 07 Nov 2025 | Direct | |||
| Kyle Carver | Series B Preferred Stock | Conversion of derivative security | -100% | -25,000 | 0 | 07 Nov 2025 | Direct | |||
| Gregory S. Moss | Common Stock | Conversion of derivative security | 3,175 | 3,175 | 07 Nov 2025 | By Trust | ||||
| Gregory S. Moss | Series B Preferred Stock | Conversion of derivative security | -100% | -25,000 | 0 | 07 Nov 2025 | By Trust | |||
| Pivotal bioVenture Partners Fund I, L.P. | Common Stock | Conversion of derivative security | 3,367,975 | 1,632,441 | 07 Nov 2025 | See footnotes |
* marks a reported price that did not pass the local price check.